Key result
While troponin and natriuretic peptides show promise as early predictors of left ventricular ejection fraction deterioration after cardiotoxic chemotherapy, insufficient evidence and lack of standardized cut-offs currently limit their routine clinical use.
Why the study?
Can troponin and natriuretic peptides predict the deterioration of left ventricular ejection fraction after chemotherapy?
Can troponin and natriuretic peptides predict the deterioration of left ventricular ejection fraction after chemotherapy?
While troponin I can predict chemotherapy-induced cardiotoxicity, its clinical utility is limited by the need for frequent serial measurements, and natriuretic peptides require further validation.
Answers are grounded in this paper and cite their sources.
Insufficient evidence limits routine use of troponin or natriuretic peptides for post-chemotherapy monitoring; leaves open their predictive role pending standardized thresholds and prospective trials.
Cardiotoxicity due to anthracyclines, trastuzumab and other potential cardiotoxic drugs is still a problem of modern chemotherapy. For years researchers have tried to find biological markers that can predict changes in the heart. The most thoroughly tested markers are troponin and natriuretic peptides. Some studies have proven that these markers can indeed be useful. In studies which have shown the predictive role of troponin I the assessment of this marker was performed very frequently. It is not possible to carry out such serial measurements in many centers because of typical 1-day hospital stay times. The predictive role of natriuretic peptides still needs further investigation. This review considers the newest research from recent years.
No takes yet. Share an insight, caveat, or question.
Stachowiak et al. (2013) conducted a review in Cardiotoxicity after chemotherapy. Troponin and natriuretic peptides was evaluated on Deterioration of left ventricular ejection fraction. While troponin and natriuretic peptides show promise as early predictors of left ventricular ejection fraction deterioration after cardiotoxic chemotherapy, insufficient evidence and lack of standardized cut-offs currently limit their routine clinical use.
Synapse has enriched 10 related papers. Consider them for comparative context: